Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Vor Biopharma (VOR) Financials

Vor Biopharma logo
$14.33 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$14.41 +0.08 (+0.56%)
As of 05/22/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Vor Biopharma

Annual Income Statements for Vor Biopharma

This table shows Vor Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -49 -70 -92 -118 -117 -696
Consolidated Net Income / (Loss)		 -43 -69 -92 -118 -117 -696
Net Income / (Loss) Continuing Operations		 -43 -69 -92 -118 -117 -696
Total Pre-Tax Income 		-43 -69 -92 -118 -117 -696
Total Operating Income		 -43 -69 -93 -126 -121 -372
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 43 69 93 126 121 372
Selling, General & Admin Expense		 12 21 29 32 28 50
Research & Development Expense		 32 48 65 94 93 322
Total Other Income / (Expense), net		 0.03 0.12 1.32 8.17 4.27 -324
Interest & Investment Income		 0.03 0.12 1.32 8.17 4.27 5.87
Other Income / (Expense), net		 - - - - 0.00 -330
Basic Earnings per Share		 ($230.57) ($2.10) ($2.33) ($1.75) ($34.03) ($70.50)
Weighted Average Basic Shares Outstanding		 213.66K 33.43M 39.55M 67.19M 3.44M 9.87M
Diluted Earnings per Share		 ($230.57) ($2.10) ($2.33) ($1.75) ($34.03) ($70.50)
Weighted Average Diluted Shares Outstanding		 213.66K 33.43M 39.55M 67.19M 3.44M 9.87M
Weighted Average Basic & Diluted Shares Outstanding		 213.66K 33.43M 66.37M 68.17M 124.85M 48.85M

Quarterly Income Statements for Vor Biopharma

This table shows Vor Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723 -220
Consolidated Net Income / (Loss)		 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723 -220
Net Income / (Loss) Continuing Operations		 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723 -220
Total Pre-Tax Income 		-33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723 -220
Total Operating Income		 -35 -28 -32 -29 -29 -31 -33 -274 -28 -36 -35
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 35 28 32 29 29 31 33 274 28 36 35
Selling, General & Admin Expense		 7.71 7.23 8.00 7.21 6.70 5.96 6.59 13 14 17 18
Research & Development Expense		 28 21 24 22 22 25 27 261 14 19 18
Total Other Income / (Expense), net		 2.13 1.86 1.52 1.20 0.95 0.60 0.81 -1,299 -785 1,759 -184
Interest & Investment Income		 2.13 1.86 1.52 1.20 0.95 0.60 0.81 0.54 1.73 2.80 3.94
Other Income / (Expense), net		 - - - 0.00 0.00 - 0.00 -1,300 -786 - -188
Basic Earnings per Share		 ($0.49) ($0.38) ($0.45) ($0.41) ($8.05) ($0.44) ($5.21) ($12.56) ($121.63) $174.52 ($5.11)
Weighted Average Basic Shares Outstanding		 67.61M 67.19M 68.03M 68.30M 3.42M 68.71M 6.24M 125.27M 6.68M 9.87M 43.01M
Diluted Earnings per Share		 ($0.49) ($0.38) ($0.45) ($0.41) ($8.05) ($0.44) ($5.21) ($12.56) ($121.63) $174.52 ($5.11)
Weighted Average Diluted Shares Outstanding		 67.61M 67.19M 68.03M 68.30M 3.42M 68.71M 6.24M 125.27M 6.68M 9.87M 43.01M
Weighted Average Basic & Diluted Shares Outstanding		 67.81M 68.17M 68.26M 68.40M 68.67M 124.85M 124.96M 126.68M 10.41M 48.85M 54.19M

Annual Cash Flow Statements for Vor Biopharma

This table details how cash moves in and out of Vor Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 42 72 -62 -26 51 312
Net Cash From Operating Activities		 -36 -69 -85 -100 -100 -143
Net Cash From Continuing Operating Activities		 -36 -69 -85 -100 -100 -143
Net Income / (Loss) Continuing Operations		 -43 -69 -92 -118 -117 -696
Consolidated Net Income / (Loss)		 -43 -69 -92 -118 -117 -696
Depreciation Expense		 0.61 1.43 2.53 3.49 3.53 2.89
Amortization Expense		 - - -0.01 -4.66 -1.15 -0.07
Non-Cash Adjustments To Reconcile Net Income		 2.12 7.33 3.82 18 15 540
Changes in Operating Assets and Liabilities, net		 4.32 -9.01 0.62 0.65 0.01 10
Net Cash From Investing Activities		 -4.16 -92 -94 71 97 -49
Net Cash From Continuing Investing Activities		 -4.16 -92 -94 71 97 -49
Purchase of Property, Plant & Equipment		 -4.16 -3.89 -8.46 -1.07 -0.23 -0.94
Purchase of Investments		 0.00 -88 -123 -75 -9.91 -54
Sale of Property, Plant & Equipment		 - - - - 0.00 0.80
Sale and/or Maturity of Investments		 - 0.00 38 147 107 5.00
Net Cash From Financing Activities		 83 233 117 2.94 53 504
Net Cash From Continuing Financing Activities		 83 233 117 2.94 53 504
Issuance of Common Equity		 0.00 190 117 4.84 56 505
Other Financing Activities, net		 0.26 - 0.00 -1.90 -2.66 -1.58

Quarterly Cash Flow Statements for Vor Biopharma

This table details how cash moves in and out of Vor Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 13 -14 14 31 -23 29 -32 141 -32 236 -227
Net Cash From Operating Activities		 -28 -24 -30 -22 -23 -24 -31 -35 -54 -23 -38
Net Cash From Continuing Operating Activities		 -28 -24 -30 -22 -23 -24 -31 -35 -54 -23 -38
Net Income / (Loss) Continuing Operations		 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723 -220
Consolidated Net Income / (Loss)		 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723 -220
Depreciation Expense		 0.89 0.89 0.94 0.87 0.85 0.87 0.83 2.04 0.00 0.02 0.03
Amortization Expense		 -1.23 -0.99 -0.80 -0.33 -0.01 -0.01 -0.01 -0.01 -0.01 -0.03 -0.49
Non-Cash Adjustments To Reconcile Net Income		 4.36 3.11 4.31 4.04 3.53 2.98 2.20 1,532 754 -1,749 197
Changes in Operating Assets and Liabilities, net		 1.27 -0.78 -4.12 1.41 -0.10 2.82 -1.59 4.63 5.06 3.16 -15
Net Cash From Investing Activities		 41 10 44 53 -0.03 -0.07 -0.23 0.65 -0.24 -49 -263
Net Cash From Continuing Investing Activities		 41 10 44 53 -0.03 -0.07 -0.23 0.65 -0.24 -49 -263
Purchase of Property, Plant & Equipment		 -0.47 -0.11 -0.11 -0.01 -0.03 -0.07 -0.23 -0.15 -0.24 -0.31 -0.05
Purchase of Investments		 0.00 -17 -9.91 -0.00 - - 0.00 - - -54 -277
Sale and/or Maturity of Investments		 41 27 54 53 - - 0.00 -0.00 - 5.00 13
Net Cash From Financing Activities		 0.18 0.03 0.10 -0.03 0.04 53 -0.61 175 22 308 75
Net Cash From Continuing Financing Activities		 0.18 0.03 0.10 -0.03 0.04 53 -0.61 175 22 308 75
Repurchase of Common Equity		 - - 0.00 - - - -0.55 - -0.64 - -0.13
Issuance of Common Equity		 0.40 0.05 0.28 0.02 0.11 56 0.00 175 22 308 75
Other Financing Activities, net		 -0.22 -0.02 -0.18 -0.05 -0.07 -2.36 -0.06 -0.03 -0.02 -1.47 -0.00

Annual Balance Sheets for Vor Biopharma

This table presents Vor Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 76 243 299 198 143 464
Total Current Assets		 49 214 237 141 97 458
Cash & Equivalents		 49 120 58 31 82 396
Short-Term Investments		 0.00 88 173 106 9.98 59
Prepaid Expenses		 0.47 4.84 4.37 3.15 4.20 1.15
Other Current Assets		 0.10 2.09 2.34 0.48 0.38 1.75
Plant, Property, & Equipment, net		 4.73 6.85 13 10 6.58 0.53
Total Noncurrent Assets		 22 21 50 47 40 5.49
Other Noncurrent Operating Assets		 22 21 50 47 40 5.49
Total Liabilities & Shareholders' Equity		 76 243 299 198 143 464
Total Liabilities		 28 26 49 47 46 628
Total Current Liabilities		 10 10 13 16 19 25
Accounts Payable		 2.36 1.55 1.77 0.82 1.51 5.13
Accrued Expenses		 6.26 6.34 7.89 11 13 20
Other Current Liabilities		 1.59 2.27 3.46 3.88 4.22 0.28
Total Noncurrent Liabilities		 17 16 36 32 28 603
Other Noncurrent Operating Liabilities		 17 16 36 32 28 603
Total Equity & Noncontrolling Interests		 -59 216 251 151 97 -164
Total Preferred & Common Equity		 -59 216 251 151 97 -164
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -59 216 251 151 97 -164
Common Stock		 2.16 346 474 491 554 989
Retained Earnings		 -61 -130 -222 -340 -457 -1,153
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.77 -0.08 0.02 0.04

Quarterly Balance Sheets for Vor Biopharma

This table presents Vor Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 251 223 167 142 116 109 205 176 507
Total Current Assets		 191 164 112 90 67 65 205 172 501
Cash & Equivalents		 32 45 45 76 53 50 191 160 170
Short-Term Investments		 155 115 63 9.86 10 9.99 9.99 10 322
Prepaid Expenses		 3.95 3.67 3.83 4.05 4.20 4.52 1.50 0.75 6.39
Other Current Assets		 0.54 0.67 0.51 0.27 0.29 0.30 0.45 1.28 2.86
Plant, Property, & Equipment, net		 11 11 9.17 8.29 7.47 5.99 0.00 0.27 0.57
Total Noncurrent Assets		 46 48 46 43 41 38 0.44 3.48 5.40
Other Noncurrent Operating Assets		 46 48 46 43 41 38 0.44 3.48 5.40
Total Liabilities & Shareholders' Equity		 251 223 167 142 116 109 205 176 507
Total Liabilities		 47 48 44 44 43 43 1,711 2,402 657
Total Current Liabilities		 13 15 13 14 14 17 59 19 16
Accounts Payable		 1.65 1.31 2.33 2.01 1.32 3.73 0.67 0.89 1.04
Accrued Expenses		 7.26 10 6.80 7.66 8.85 8.69 58 18 15
Other Current Liabilities		 3.81 3.81 4.09 4.14 4.18 4.31 0.00 0.25 0.31
Total Noncurrent Liabilities		 34 33 31 30 29 27 1,652 2,383 641
Other Noncurrent Operating Liabilities		 34 33 31 30 29 27 1,652 2,383 641
Total Equity & Noncontrolling Interests		 204 175 123 98 73 66 -1,506 -2,225 -150
Total Preferred & Common Equity		 204 175 123 98 73 66 -1,506 -2,225 -150
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 204 175 123 98 73 66 -1,506 -2,225 -150
Common Stock		 486 489 494 497 499 556 557 650 1,223
Retained Earnings		 -281 -314 -371 -399 -426 -489 -2,063 -2,876 -1,373
Accumulated Other Comprehensive Income / (Loss)		 -0.44 -0.28 -0.09 -0.07 0.07 0.02 0.01 0.01 -0.71

Annual Metrics And Ratios for Vor Biopharma

This table displays calculated financial ratios and metrics derived from Vor Biopharma's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 37,289,504.00 38,666,158.00 67,805,687.00 - 10,410,630.00
DEI Adjusted Shares Outstanding		 0.00 1,864,475.00 1,933,308.00 3,390,284.00 - 10,410,630.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -37.61 -47.64 -34.76 - -66.85
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -30 -48 -65 -88 -85 -260
Return On Investment Capital (ROIC_SIMPLE)		 - - - -58.53% -87.76% 158.33%
Earnings before Interest and Taxes (EBIT)		 -43 -69 -93 -126 -121 -702
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -43 -68 -91 -127 -119 -699
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -57 -77 -81 -76 364
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.27 8.79 20 14 4.74 -620
Increase / (Decrease) in Invested Capital		 0.00 9.06 12 -6.81 -8.81 -624
Book Value per Share		 ($276.45) $5.80 $6.48 $2.22 $1.41 ($15.78)
Tangible Book Value per Share		 ($276.45) $5.80 $6.48 $2.22 $1.41 ($15.78)
Total Capital		 48 216 251 151 97 -164
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -49 -207 -230 -137 -92 -455
Capital Expenditures (CapEx)		 4.16 3.89 8.46 1.07 0.23 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.64 -3.22 -6.41 -12 -14 -22
Debt-free Net Working Capital (DFNWC)		 39 204 224 125 78 433
Net Working Capital (NWC)		 39 204 224 125 78 433
Net Nonoperating Expense (NNE)		 13 21 27 30 32 436
Net Nonoperating Obligations (NNO)		 -49 -207 -230 -137 -92 -455
Total Depreciation and Amortization (D&A)		 0.61 1.43 2.51 -1.17 2.38 2.82
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.10) ($2.33) ($1.75) ($1.70) ($70.50)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 37.49M 39.55M 67.19M 68.71M 9.87M
Adjusted Diluted Earnings per Share		 $0.00 ($2.10) ($2.33) ($1.75) ($1.70) ($70.50)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 37.49M 39.55M 67.19M 68.71M 9.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.10) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 33.43M 66.37M 68.17M 124.85M 48.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -48 -65 -88 -85 -260
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Vor Biopharma

This table displays calculated financial ratios and metrics derived from Vor Biopharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 67,538,680.00 67,805,687.00 68,168,771.00 68,259,602.00 68,398,826.00 - 124,851,547.00 124,959,520.00 126,683,111.00 10,410,630.00 48,847,504.00
DEI Adjusted Shares Outstanding		 3,376,934.00 3,390,284.00 3,408,439.00 3,412,980.00 3,419,941.00 - 6,242,577.00 6,247,976.00 6,334,156.00 10,410,630.00 48,847,504.00
DEI Earnings Per Adjusted Shares Outstanding		 -9.83 -7.75 -9.04 -8.16 -8.06 - -5.20 -251.87 -128.30 165.49 -4.50
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -45.39% -17.06% -4.52% 12.46% 22.38% -7.94% -0.92% -5,417.39% -2,843.03% - -589.66%
EBIT Growth		 -46.53% -13.75% -6.26% 9.76% 19.26% -11.33% -2.99% -5,321.75% -2,756.29% - -571.41%
NOPAT Growth		 -46.53% -13.75% -6.26% 9.76% 19.26% -11.33% -2.99% -844.67% 1.42% - -5.61%
Net Income Growth		 -39.52% -9.83% -8.34% 7.14% 16.97% -16.95% -5.46% -5,552.75% -2,848.89% - -575.94%
EPS Growth		 22.22% 25.49% -4.65% 8.89% 16.97% -15.79% 42.22% -2,963.41% -1,410.93% - 1.92%
Operating Cash Flow Growth		 -47.59% -30.96% -25.54% 9.35% 16.54% -0.15% -1.97% -61.05% -130.46% - -23.11%
Free Cash Flow Firm Growth		 48.58% 55.42% 36.20% -25.86% 7.86% -1.81% 24.15% 8,921.06% 15,574.03% - 4,623.18%
Invested Capital Growth		 -35.22% -33.46% -22.28% -19.78% -30.90% -65.03% -61.21% -14,172.46% -23,714.72% - -10,738.86%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 -9.53% 20.85% -14.04% 11.45% 2.88% -10.06% -6.63% -4,740.90% 48.20% - -522.67%
EBIT Q/Q Growth		 -9.77% 20.36% -14.94% 10.18% 1.80% -9.81% -6.32% -4,628.62% 48.27% - -521.58%
NOPAT Q/Q Growth		 -9.77% 20.36% -14.94% 10.18% 1.80% -9.81% -6.32% -723.90% 89.75% - 31.56%
Net Income Q/Q Growth		 -10.71% 20.88% -17.30% 9.63% 1.01% -11.44% -5.78% -4,744.15% 48.36% - -112.75%
EPS Q/Q Growth		 -8.89% 22.45% -18.42% 8.89% 1.01% -10.00% 40.91% -4,730.77% -868.39% - -102.93%
Operating Cash Flow Q/Q Growth		 -15.76% 13.88% -26.80% 28.29% -6.58% -3.34% -29.10% -13.26% -52.52% - -67.74%
Free Cash Flow Firm Q/Q Growth		 -21.54% 23.08% -41.13% 4.61% 11.02% 15.01% -5.15% 11,193.12% 56.10% - 5.96%
Invested Capital Q/Q Growth		 -2.99% -7.72% 14.81% -21.95% -16.44% -53.30% 27.35% -28,417.50% -40.22% - -3.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 93.98% 93.38% 95.29% 95.88% 96.65% 98.09% 97.58% 99.97% 99.79% - 98.24%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -69.27% -58.74% -68.07% -78.07% -90.79% -94.52% -125.43% 236.49% 227.60% - 2,093.72%
Cash Return on Invested Capital (CROIC)		 -416.93% -480.15% -478.47% -618.60% -628.79% -831.39% -703.87% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -69.27% -58.74% -68.07% -78.07% -90.79% -94.52% -125.43% 236.49% 227.60% - 2,093.72%
Return on Equity Simple (ROE_SIMPLE)		 -66.09% 0.00% -97.72% 0.00% 0.00% 0.00% -179.50% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -20 -23 -20 -20 -22 -23 -192 -20 -36 -25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.72% -3.58% -5.15% -5.46% -6.82% -7.68% -10.96% -956.45% -679.90% - -70.70%
Return On Investment Capital (ROIC_SIMPLE)		 - -13.06% -18.39% -20.72% -27.36% -22.67% -35.27% 12.75% 0.88% 21.89% 16.36%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -35 -28 -32 -29 -29 -31 -33 -1,574 -814 -36 -224
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -28 -32 -28 -28 -30 -32 -1,572 -814 -36 -224
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.82 1.01 1.31 0.70 0.66 0.79 1.36 0.00 0.00 - 0.00
Price to Tangible Book Value (P/TBV)		 0.82 1.01 1.31 0.70 0.66 0.79 1.36 0.00 0.00 - 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.14 3.48 0.00 0.00 0.00 4.90 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 - 0.98
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -0.89 -0.92 -0.90 -0.91 -0.90 -0.93 -0.89 0.21 0.11 - 6.54
Leverage Ratio		 1.29 1.24 1.26 1.30 1.37 1.38 1.46 -0.25 -0.14 - -7.30
Compound Leverage Factor		 1.21 1.16 1.20 1.24 1.32 1.35 1.43 -0.25 -0.14 - -7.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 0.09 -0.18 -0.84 -3.03 -4.74 -3.56 -5.50 -38.43 -36.97 - -3.30
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.69 9.04 8.46 6.54 4.69 5.19 3.88 3.49 9.16 - 31.15
Quick Ratio		 10.40 8.81 8.13 6.23 4.38 4.94 3.59 3.41 9.05 - 30.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -17 -13 -18 -17 -15 -13 -14 1,529 2,386 588 623
Operating Cash Flow to CapEx		 -5,999.57% -21,645.05% -26,723.68% -242,744.44% -68,485.29% -33,420.83% -13,448.48% -23,147.37% -21,992.62% - -79,679.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 15 14 16 12 10 4.74 6.03 -1,709 -2,396 -620 -642
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 -7.98 -6.81 -4.46 -2.99 -4.54 -8.81 -9.52 -1,721 -2,406 -624 -648
Enterprise Value (EV)		 -17 15 54 -18 -15 -16 30 -0.54 138 - 380
Market Capitalization		 143 153 162 68 48 76 90 202 309 - 871
Book Value per Share		 $2.59 $2.22 $1.80 $1.44 $21.31 $1.41 $0.53 ($12.05) ($17.57) ($15.78) ($3.08)
Tangible Book Value per Share		 $2.59 $2.22 $1.80 $1.44 $21.31 $1.41 $0.53 ($12.05) ($17.57) ($15.78) ($3.08)
Total Capital		 175 151 123 98 73 97 66 -1,506 -2,225 -164 -150
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -160 -137 -107 -86 -63 -92 -60 -203 -170 -455 -492
Capital Expenditures (CapEx)		 0.47 0.11 0.11 0.01 0.03 0.07 0.23 0.15 0.24 0.31 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -12 -8.88 -9.48 -9.86 -14 -12 -57 -17 -22 -6.82
Debt-free Net Working Capital (DFNWC)		 149 125 99 76 53 78 48 146 154 433 485
Net Working Capital (NWC)		 149 125 99 76 53 78 48 146 154 433 485
Net Nonoperating Expense (NNE)		 8.47 6.57 8.18 7.51 7.60 8.79 9.18 1,382 793 -1,759 195
Net Nonoperating Obligations (NNO)		 -160 -137 -107 -86 -63 -92 -60 -203 -170 -455 -492
Total Depreciation and Amortization (D&A)		 -0.33 -0.09 0.15 0.54 0.84 0.85 0.81 2.03 -0.01 -0.01 -0.46
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.49) ($0.38) ($0.45) ($0.41) ($8.00) ($0.44) ($0.26) ($12.56) ($121.63) $174.52 ($5.11)
Adjusted Weighted Average Basic Shares Outstanding		 67.61M 67.19M 68.03M 68.30M 3.42M 68.71M 124.82M 125.27M 6.68M 9.87M 43.01M
Adjusted Diluted Earnings per Share		 ($0.49) ($0.38) ($0.45) ($0.41) ($8.00) ($0.44) ($0.26) ($12.56) ($121.63) $174.52 ($5.11)
Adjusted Weighted Average Diluted Shares Outstanding		 67.61M 67.19M 68.03M 68.30M 3.42M 68.71M 124.82M 125.27M 6.68M 9.87M 43.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $174.52 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 67.81M 68.17M 68.26M 68.40M 3.43M 124.85M 124.96M 126.68M 10.41M 48.85M 54.19M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -20 -23 -20 -20 -22 -23 -192 -20 -25 -25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Vor Biopharma's quarterly statements, focusing on the last four years of data provided (2023–2025). Note: 2022 data is not included in the dataset.

  • In Q4 2025, Vor Biopharma reported a very large Net Income figure of about $1.72B, driven by a one-time Total Other Income / (Expense), net of about $1.76B. This non-operating gain boosted earnings but is unlikely to be repeatable in normal operations.
  • Q4 2025 saw a substantial equity raise: Issuance of Common Equity of about $308.1M, contributing to a net financing cash inflow of roughly $307.8M for the quarter.
  • Across 2025, financing activity provided about $0.505B of net cash from financing activities (roughly $0.096M in Q1, $175.1M in Q2, $21.5M in Q3, and $307.8M in Q4), highlighting ongoing access to capital markets.
  • Q4 2025 also produced a positive net change in cash and equivalents of about $236.0M, aided by the financing inflows.
  • Total Revenue remained at zero across the 2025 quarters, consistent with Vor Biopharma's pre-revenue, development-stage business model.
  • Operating cash burn persists: net cash from operating activities was negative in 2025 (e.g., Q4 approximately -$22.9M) and negative in multiple prior quarters, indicating ongoing cash burn before financing activities.
  • Balance sheet risk is evident: in Q3 2025, Total Liabilities were about $2.40B against Total Assets of about $176M, implying negative shareholders’ equity of roughly $2.23B and a high leverage/funding-reliant position.
  • No product revenue is evident in many quarters, with substantial R&D and SG&A expenses driving operating losses in 2025, underscoring the company’s reliance on external financing to fund operations.
  • Occasional sizable non-operating swings (e.g., large fluctuations in Other Income / (Expense)) can drive reported profits in certain periods, making sustainability of earnings questionable and adding investment risk.
05/25/26 09:07 PM ETAI Generated. May Contain Errors.

Vor Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Vor Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Vor Biopharma's net income appears to be on an upward trend, with a most recent value of -$695.98 million in 2025, rising from -$43.34 million in 2020. The previous period was -$116.91 million in 2024. See where experts think Vor Biopharma is headed by visiting Vor Biopharma's forecast page.

Vor Biopharma's total operating income in 2025 was -$371.64 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $371.64 million

Over the last 5 years, Vor Biopharma's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Vor Biopharma's total liabilities were at $628.44 million at the end of 2025, a 1,259.5% increase from 2024, and a 2,173.9% increase since 2020.

In the past 5 years, Vor Biopharma's cash and equivalents has ranged from $31.36 million in 2023 to $396.49 million in 2025, and is currently $396.49 million as of their latest financial filing in 2025.

Over the last 5 years, Vor Biopharma's book value per share changed from -276.45 in 2020 to -15.78 in 2025, a change of -94.3%.


Related Companies

Financial statements for NASDAQ:VOR last updated on 5/15/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel